Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and/or olaparib versus weekly paclitaxel in recurrent or advanced endometrial cancer
2016-004617-28Phase 2Unknown
- Sponsor
- The University of Manchester
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in endometrial cancer (EC) and endometrial carcinosarcoma comparing Cediranib + weekly paclitaxel, Olaparib and Weekly paclitaxel (3 arms). Primary endpoint: Progression-free survival rate at 3 months. Status: unknown.
02
Drugs
cediranibolaparibpaclitaxel
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on 2016-004617-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004617-28.